Tumor Burden Monitoring
Tumor Burden Monitoring - Related Videos
04:29
Monitoring Neutrophil Recruitment Dynamics and Bacterial Burden at the Infection Site in a Murine Model
0 Views •
2025
This video demonstrates in vivo imaging to study the neutrophil recruitment dynamics at an infection site in an immunocompromised, transgenic mouse with GFP-expressing neutrophils. It involves injecting luminescent bacteria to cause an infection. This leads to neutrophil recruitment to the infection site, whose tracking is done by imaging.
07:12
Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
0 Views •
Cited by 29 •
2016
Bioluminescence imaging is a well-known tool for localizing tumors and metastases, but quantification of these images often requires complex calculations and particular instruments. We describe the easy-to-use luminoscore method, based on precise acquisition conditions, requiring no calculations, and enabling tumor burden and treatment response to be monitored in mouse models.
06:26
PTM Based Tumor Microenvironment Monitoring: A Method for Tracking Changes in ECM Rigidity Using Tumor Spheroids
0 Views •
2023
This protocol describes a technique for monitoring extracellular matrix rigidity changes by using particle-tracking microrheology (PTM). This is done by culturing 3D pancreatic tumor spheroids into ECM with embedded fluorescent probes for video particle-tracking and analysis.
03:07
Morphological and Physiological Monitoring of Tumor Spheroids Using Optical Coherence Tomography
0 Views •
2025
Source: Huang, Y. et. al., Longitudinal Morphological and Physiological Monitoring of Three-dimensional Tumor Spheroids Using Optical Coherence Tomography. J. Vis. Exp. (2019)This video demonstrates the use of optical coherence tomography (OCT) to monitor tumor spheroids in a multi-well plate by capturing high-resolution cross-sectional images. By analyzing light reflections from cellular structures, OCT constructs 3D models to assess morphological features like size and shape while also...
10:35
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
0 Views •
Cited by 18 •
2010
To study in vivo tumor growth and tumor microenvironment, we used a syngeneic and orthotopic mouse model of ovarian cancer in immunocompetent animals. We transduced a mouse tumor cell line (MOV1) with Katushka fluorescent protein (MOV1KAT) and here we show its orthotopic implantation in ovary and in vivo imaging.
FAQs
Serial imaging reveals the direction and timing of change rather than relying on one snapshot. Repeated computed tomography or magnetic resonance imaging can show whether lesions grow, shrink, or remain stable across defined time points. This temporal pattern helps distinguish an ongoing treatment response from progression and provides a consistent basis for comparing disease status during cancer research studies.
Each measurement captures a different aspect of disease status. Dimensions and volume quantify the size of tumors, while distribution indicates where disease is present. Disease-associated biomarkers add biological information that may complement structural imaging. Combining these measures can provide a more informative assessment of treatment effects, particularly when size changes alone do not fully describe the observed response.
A decrease in tumor dimensions or volume may support evidence of treatment response, whereas increasing measurements can indicate disease progression. Stable measurements may represent disease control without measurable shrinkage. When structural changes are evaluated alongside disease-associated biomarkers over time, researchers can better relate observed changes to therapeutic efficacy, progression, or possible resistance.
A study first establishes comparable assessment time points and selects relevant measurements, such as imaging-based dimensions, volume, distribution, or disease-associated biomarkers. Researchers then collect these measures serially, document changes, and compare results across time points or experimental groups. Linking the measurements with treatment exposure and biological mechanisms supports interpretation of efficacy, progression, and resistance.
Standardized monitoring applies the same measurement strategy across groups and repeated assessments. Consistent use of imaging, tumor measurements, volume estimates, distribution information, or biomarkers reduces ambiguity when researchers compare disease status. This improves the interpretability of treatment-related changes and strengthens conclusions about therapeutic efficacy in both preclinical studies and clinical trials.
The approach is useful when researchers need to evaluate therapeutic efficacy, follow disease progression, or investigate resistance during a study. In preclinical experiments and clinical trials, repeated measurements connect changes in tumor burden with biological mechanisms and patient outcomes. These links help determine whether an intervention produces measurable disease control and support comparisons among experimental groups.